论文信息 - Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers - 字舞流文

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

N. Suttorp | V. Corman | C. Drosten | L. Sander | F. Kurth | K. Kappert | F. Klein | H. Gruell | P. Tober-Lau | J. Seybold | K. Vanshylla | T. Schwarz | D. Hillus | I. Landgraf

[1] A. Huppert,et al. Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel , 2021, medRxiv.

[2] C. von Kalle,et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[3] B. Mizrahi,et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.

[4] P. Dormitzer,et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine , 2021, medRxiv.

[5] A. Hayward,et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 , 2021, The Lancet.

[6] C. von Kalle,et al. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany , 2021, Emerging infectious diseases.

[7] M. Hernán,et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[8] A. Sette,et al. Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.